Appointment of Chief Financial Officer
17 June 2026
Malvern International PLC
("Malvern" or the "Company")
Appointment of Chief Financial Officer (CFO)
Malvern International plc (AIM: MLVN), the global learning and skills development partner, is pleased to announce the appointment of Daniel Chaffer as an executive director and CFO Designate with effect from 22 June 2026.
Daniel will work closely with the outgoing CFO, Dan Fisher, over the next few months ensuring a smooth and efficient handover. He will assume the role of CFO during the transition period prior to the departure of Dan Fisher in September 2026.
Daniel Chaffer is an experienced CFO and strategic finance leader with over 25 years' experience across professional services, technology, music and the pharmaceutical industries. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Most recently, Daniel served as CFO of Sentric Music Group, a technology-driven music publishing business with £66m revenue, where he led the business through significant organic growth and post-acquisition financial integration. Prior to this he served as CFO of Bioscript Group, a PE-backed medical communications consultancy, overseeing a period of rapid growth from £8m to £28m revenue over a 4-year period, and the successful sale of the business to private equity. Earlier in his career Daniel spent nearly eight years at the BBC as a Finance Business Partner supporting high-profile production and commissioning departments.
Richard Mace, Chief Executive Officer, commented:
"The Board is delighted to have secured someone with Daniel's depth of experience, and to have done so in good time to facilitate an orderly handover at an exciting and busy time for the Group as it looks to build student numbers across its university pathway contracts and summer junior programmes. I would also like to thank Daniel Fisher for his significant contribution to Malvern and for his support in ensuring a smooth transition."
Daniel Chaffer, aged 48, currently holds no other directorships, and holds no ordinary shares or options in the Company.
Current directorships
Past directorships held within the last five years
None
Sentric Music Ltd
Masstrax Music Ltd
Sentric Music Group Ltd
Black Rock Publishing Ltd
IQ Music Ltd
Sentric Music Publishing Ltd
Cancer Communications Ltd
Cancer Communications and Consultancy Ltd
Meridian Healthcomms Ltd
Meridian Healthcomms Holdings Ltd
Portland Medical Communications Ltd
Valid Insight Ltd
Bioscript Midco 2 Ltd
Bioscript Midco 1 Ltd
Sapience Medical Education Ltd
Fortis Digital Ltd
Fortis Pharma Consulting Ltd
Azimuth Pharma Ltd
Bioscript Holdings Ltd
Bioscript Ltd
There is no other information that is required to be disclosed pursuant to Schedule 2 paragraph (g) or Rule 17 of the AIM Rules for Companies.
For further information, please contact:
Malvern International Plc
Richard Mace - Chief Executive Officer
Via Zeus
Zeus - Nominated Adviser and Broker
Mike Coe / James Bavister
https://zeuscapital.co.uk/
0203 829 5000
Notes to Editors:
Malvern International is a learning and language skills development partner, offering international students essential academic and English language skills, cultural experiences and the support they need to thrive in their academic studies, daily life and career development.
University Pathways provides on-and off-campus in-sessional and pre-sessional programmes to support international students in progressing to a wide range of universities and undergraduate courses. Malvern assists its university partners with international student recruitment and conversion, admissions, fee collection, and course delivery, including teaching, orientation, and student support.
English Language Teaching is provided to young learners through fully immersive residential English language centres and customised language programmes at high-quality locations.
For further investor information go to www.malverninternational.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDBOABLGDLLSBDGLL
